Citadel Advisors’s Immunomedics Inc IMMU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-528,400
Closed -$44.9M 11881
2020
Q3
$44.9M Buy
528,400
+76,600
+17% +$3.87M 0.01% 936
2020
Q2
$16M Buy
451,800
+239,700
+113% +$7.01M 0.01% 1702
2020
Q1
$2.86M Sell
212,100
-187,200
-47% -$3.15M ﹤0.01% 3538
2019
Q4
$8.45M Buy
399,300
+66,100
+20% +$1.17M ﹤0.01% 2400
2019
Q3
$4.42M Buy
333,200
+178,800
+116% +$2.63M ﹤0.01% 3278
2019
Q2
$2.14M Sell
154,400
-56,300
-27% -$847K ﹤0.01% 4406
2019
Q1
$4.05M Sell
210,700
-274,400
-57% -$4.42M ﹤0.01% 3289
2018
Q4
$6.92M Buy
485,100
+170,600
+54% +$3.39M ﹤0.01% 2348
2018
Q3
$6.55M Sell
314,500
-15,300
-5% -$362K ﹤0.01% 2632
2018
Q2
$7.81M Buy
329,800
+96,300
+41% +$1.94M ﹤0.01% 2202
2018
Q1
$3.41M Sell
233,500
-108,700
-32% -$1.78M ﹤0.01% 2963
2017
Q4
$5.53M Buy
342,200
+121,700
+55% +$1.44M ﹤0.01% 2366
2017
Q3
$3.08M Buy
220,500
+102,600
+87% +$1.02M ﹤0.01% 2886
2017
Q2
$1.04M Buy
117,900
+13,500
+13% +$94.8K ﹤0.01% 4025
2017
Q1
$675K Buy
104,400
+13,400
+15% +$67.9K ﹤0.01% 4558
2016
Q4
$334K Buy
91,000
+4,900
+6% +$14.5K ﹤0.01% 5530
2016
Q3
$280K Sell
86,100
-19,500
-18% -$54.5K ﹤0.01% 5789
2016
Q2
$245K Buy
105,600
+42,500
+67% +$142K ﹤0.01% 5514
2016
Q1
$158K Sell
63,100
-63,700
-50% -$143K ﹤0.01% 5797
2015
Q4
$389K Buy
126,800
+4,000
+3% +$11.2K ﹤0.01% 4824
2015
Q3
$211K Sell
122,800
-50,400
-29% -$129K ﹤0.01% 6077
2015
Q2
$703K Buy
173,200
+56,500
+48% +$231K ﹤0.01% 4464
2015
Q1
$447K Buy
116,700
+18,400
+19% +$80K ﹤0.01% 5069
2014
Q4
$472K Buy
98,300
+5,000
+5% +$19.8K ﹤0.01% 4809
2014
Q3
$347K Buy
93,300
+10,700
+13% +$36.2K ﹤0.01% 5086
2014
Q2
$301K Buy
82,600
+700
+0.9% +$2.57K ﹤0.01% 5068
2014
Q1
$345K Sell
81,900
-161,100
-66% -$799K ﹤0.01% 4857
2013
Q4
$1.12M Buy
243,000
+19,500
+9% +$86.8K ﹤0.01% 3123
2013
Q3
$1.38M Buy
223,500
+39,600
+22% +$228K ﹤0.01% 2770
2013
Q2
$1M Buy
+183,900
New +$604K ﹤0.01% 3189

Citadel Advisors's IMMU Position: Q4 2020 in Review

Citadel Advisors sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 2,506,602 shares — an estimated $213M sold.

Citadel Advisors first reported a position in IMMU in Q2 2013 and held it in 26 quarters. The position peaked at $213M in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.

  • Citadel Advisors reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
  • Citadel Advisors sold 2,506,602 Immunomedics Inc shares in Q4 2020, an estimated $213M.
  • Citadel Advisors first reported a position in Immunomedics Inc in Q2 2013 and held it in 26 quarters.
  • Citadel Advisors's Immunomedics Inc position peaked at $213M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.

Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.